The current price-to-earnings ratio of AMRX can't be determined, as the TTM EPS of -$0.48 is negative. Amneal Pharmaceuticals's last PE ratio on record was 70.33 in September 2023.
The mean historical PE ratio of Amneal Pharmaceuticals over the last four years is 69.94. In the past four years, AMRX's PE ratio was at its highest in the Mar 2022 quarter at 208.5, with a price of $4.17 and an EPS of $0.02. The Dec 2020 quarter recorded the bottom point at 7.37, with a price of $4.57 and an EPS of $0.62.
Maximum annual increase: 828.49% in 2021
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | N/A | N/A |
| 2021 | 68.43 | 828.49% |
| 2020 | 7.37 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
| Stock name | PE ratio | Market cap |
|---|---|---|
| NWBO Northwest Biotherapeutics Inc | N/A | $547.39M |
| AMRX Amneal Pharmaceuticals Inc | N/A | $2.08B |
The current price to earnings ratio of AMRX can't be calculated, as its EPS of -$0.48 is negative.
As an average over the last 3 years, AMRX stock has a PE ratio of 94.76.
As an average over the last 5 years, AMRX stock has a PE ratio of 69.94.
The highest quarterly PE ratio in the last four years has been 208.5 and it was in the Mar 2022 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.